BAY-6096
Probe criteria
| Control compound (100 times less potent than the probe) | BAY-726: human ADRA2B: IC50 = 7.1 µM, dog (IC50 = 10 µM) (Cell-based assay); Clean adrenergic receptor panelTwo off targets in the PDSP scan (43 targets at 10 µM): HTR1A (Ki = 212.03 nM), ADRA2B (Ki = 2755.96 nM) |
| On target cell activity for cell-based targets: goal is < 1 µM IC50/EC50 | Surpasses criterion: human ADRA2B: IC50 = 14 nM (Cell-based assay). Rat (IC50 = 13 nM), Dog (IC50 = 25 nM); mutant human ADRA2B (deletion of three glutamate residues in an acidic stretch of 18 amino acids (of which 15 are glutamates) located in the third intracellular loop, has a higher risk for myocardial infarction): IC50 = 25 nM The ADRA2B is located on the cellular surface. |
| Inhibitor/agonist potency: goal is < 100 nM (IC50, Kd) | Surpasses criterion: Ki = 21 nM (Radioactive binding assay for human ADRA2B, Panlabs) |
| Selectivity within target family: > 30-fold | Adrenergic receptor panel (IC50): ADRA1A (5.516 µM; 394- fold), ADRA1B (> 10 µM), ADRA1D (> 10 µM), ADRA2A (10 µM), ADRA2C (>11.83 µM), ADRB1 (> 10 µM), ADRB2 (> 10 µM), ADRB3 (> 10 µM)Clean PDSP scan (43 targets at 10 µM) except for ADRA2B (Ki = 44.35 nM) |
| Selectivity outside target family | Eurofins Panlabs panel (67 targets) at 10 µM: clean In-house kinase panel (22 kinases): human DDR2: IC50 = 1.4 µM, others IC50 > 20 µM |